Centessa Pharmaceuticals (CNTA) Non-Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Non-Current Assets data on file, last reported at $293.1 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $293.1 million, up 62.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $945.1 million (up 209.65% YoY), and the FY2025 annual result was $319.6 million, up 691.35% from the prior year.
• Non-Current Assets declined to $293.1 million in Q1 2026 per CNTA's latest filing, from $319.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $319.6 million in Q4 2025 and troughed at $993000.0 in Q1 2022.
• A 5-year average of $85.7 million and a median of $43.3 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 2637.15% in 2023, then dropped 10.55% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $6.6 million in 2022, then soared by 588.32% to $45.2 million in 2023, then fell by 10.55% to $40.4 million in 2024, then jumped by 691.35% to $319.6 million in 2025, then declined by 8.3% to $293.1 million in 2026.
• Business Quant data shows CNTA's Non-Current Assets at $293.1 million in Q1 2026, $319.6 million in Q4 2025, and $140.6 million in Q3 2025.